Novo Nordisk upgrades guidance
The Danish pharmaceutical giant has upgraded its full-year financial guidance due to the growth in market shares for diabetes drug Ozempic being higher than expected and market growth for the other GLP analogs. Obesity drug sales, mostly in the US, are also highlighted as significant.
by christopher due karlsson, translated by catherine brett
Novo Nordisk has raised its sales and operating outlook for 2021.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Novo Nordisk hopes to stabilize Wegovy supply in early 2022
For subscribers
